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Abstract 
BACKGROUND: High expression of matrix metalloproteinase 9 (MMP9) during vascular injury 
and inflammation plays an important role in atherosclerotic plaque formation and rupture. In 
the process of atherosclerosis, oxidized low-density lipoprotein (oxLDL) upregulates MMP9 in 
human aortic vascular smooth muscle cells (HA/VSMCs). Adiponectin is an adipose tissue-
derived hormone that has been shown to exert anti-atherogenic and anti-inflammatory effects. 
The aim of this study was to investigate the effect of adiponectin on MMP9 expression under 
pathogenic condition created by oxLDL in HA/VSMCs. 
METHODS: In this experimental study, HA/VSMC were stimulated with oxLDL alone and in the 
presence of adiponectin for 24 and 48 h. The expression of MMP9 gene was determined by real-
time polymerase chain reaction method. The protein level of this gene was investigated by 
western blotting technique. 
RESULTS: An oxLDL increased MMP9 expression 2.16 ± 0.24- and 3.32 ± 0.25-fold after 24 and 
48 h, respectively and adiponectin decreased oxLDL-induced MMP9 expression in a time-
dependent manner. 
CONCLUSION: These results show that adiponectin changes extracellular matrix by reducing 
MMP9 mRNA and protein, therefore, may stabilize lesions and reduce atheroma rupture. 
 
Keywords: Matrix Metalloproteinase 9, Adiponectin, Oxidized Low Density Lipoprotein 
 
Date of submission: 5 Apr 2014, Date of acceptance: 23 Feb 2015 
 
Introduction 
Atherosclerosis is a multifactorial disease that 
remains one of the leading causes of mortality 
worldwide.1 Obesity and its dependence on the 
pathogenesis of cardiovascular disease have evoked 
great interest in understanding the impact of 
adipokine secreted from adipose tissue on 
atherosclerosis.2 It has been well established that 
adipose tissue constitutes a versatile endocrine gland 
in the body and is actively involved in the regulation 
of many biological processes.3 Some adipose tissue-
derived factors have proinflammatory activity and, 
in contrast, some factors like adiponectin inhibit 
inflammatory processes.4 Fluctuation in adipokines 
is a key mechanism that connects obesity to 
increased risk of vascular complications.5 
Adiponectin has attracted special attention of 
investigators because of its ability to impact 
cardiovascular disease.6 According to clinical 
studies, high molecular weight form of adiponectin 
is more clinically relevant7 because it exerts the 
protective effects on vascular diseases.8 
Matrix metalloproteinases (MMP) are a family of 
zinc-dependent proteolytic enzymes, which are 
collectively capable of degrading various 
components of the extracellular matrix.9 
Human epidemiological and genetic studies 
show that (MMP9) is the strongest candidate for 
inducing plaque rupture.10,11 These studies 
confirmed that MMP9 played a basic role in 
progression of arterial lesions because it regulated 
vascular smooth muscle cells (VSMCs) proliferation 
and migration into the intima.12 Several studies have 
indicated that oxidized low-density lipoprotein 
(oxLDL) induced MMP9 gene expression in 
smooth muscle cells and macrophages.13-15 It is well 
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known that oxLDL is involved in the induction and 
also in the progression of atherosclerosis.16 
Furthermore, it is responsible for destabilizing 
plaques through increased expression of 
metalloproteinases.17 However, the functions of 
adiponectin in atherosclerosis have not yet been 
fully understood. Further research regarding the 
mechanism of adiponectin action will lead to 
better understanding of the pathogenesis of 
atherosclerosis. Due to importance role of oxLDL 
and MMP9 in atheroma formation and 
progression, it seems that atheroma progression 
can be reduced by using adiponectin. The purpose 
of this study was to investigate the effect of 
adiponectin on MMP9 expression under 
pathogenic condition created by oxLDL in human 
aortic VSMCs (HA/VSMCs). 
Materials and Methods 
In this experimental study, HA/VSMCs prepared 
from Pasteur Institute of Iran were maintained in 
F12K medium. F12 media contained 0.05 mg/ml 
ascorbic acid, 0.01 mg/ml insulin, 0.01 mg/ml 
transferrin, 10 ng/ml sodium selenite, 0.03 mg/ml 
endothelial cell growth supplement, 2-[4-(2-
hydroxyethyl)piperazin-1-yl] ethanesulfonic acid 
(HEPES) to a final concentration of 10 mm, TES to 
a final concentration of 10 mm, 100 U/ml 
penicillin, 100 µg/ml streptomycin, and 0.01% 
amphotericin B. HA/VSMCs between passages 3 
and 7 were used in this experiment. For treatment, 
we seed HA/VSMCs into 12-well plate at a density 
of 15 × 103 cells/well and incubated them at 37 °C 
in 5% CO2. Cells achieving 80% confluence were 
treated by oxLDL.18 We treated cells with oxLDL 
(100 µg/ml)17 alone and in combination with 
adiponectin (5 µg/ml)19 for 24 and 48 h. The cells 
without any treatment were used as the control. 
The treated cells were washed with cold 
phosphate-buffered saline (PBS). Total RNA was 
extracted with Biozol reagent (BioFlux-China), 
according to the manufacturer’s instructions. Total 
RNA concentration and quality were evaluated by 
NanoDrop spectrophotometer (Thermo-USA). The 
single stranded cDNA was synthesized using cDNA 
Synthesis Kit (Thermo, Canada) with 1 µg total 
RNA. The cDNA was amplified by real time-
polymerase chain reaction (PCR) using SYBR® 
Green PCR Master Mix (Qiagen, Germany). Gene 
expression was detected by Rotor-Gene 3000 
(Corbett, Australia). Results were normalized against 
the housekeeping gene glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) mRNA. 
Primers for MMP9 were as follows: Forward: 5'-
GCTCACCTTCACTCGCGTGTA-3',  
reverse: 5'-TCCGTGCTCCGCGACA-3',  
and primers for GAPDH; forward: 5'- 
ACACCCACTCCTCCACCTTTG -3', reverse: 5'- 
TCCACCACCCTGTTGCTGTAG -3'. The 
temperature profile for the reaction was an initial 
stage of 95 °C for 5 min then 40 cycles of 95 °C for 
15 s, 59 °C for 20 s, and 72 °C for 30 s. Results 
were normalized against the housekeeping gene 
GAPDH mRNA. Data analysis was performed on 
the basis of the comparative delta CT method with 
the formula 2-∆∆CT to perform relative quantification 
of target genes (gene expression). 
To determine MMP9 expression at the protein 
level, cells were washed with PBS and lysed with 
radioimmunoprecipitation assay (RIPA) buffer 
containing protease inhibitor cocktail. The lysates were 
centrifuged at 10,000 g for 10 min at 4 °C. To equalize 
the concentrations, protein concentrations were 
determined by NanoDrop spectrophotometer. Protein 
lysates with an equal volume of Lameli buffer (0.125 
M Tris-HCl 4%, sodium dodecyl sulfate (SDS) 20%, 
glycine 10%, and 2-mercaptoethanol) were mixed and 
boiled for 5 min. To separate based on the size equal 
amounts of protein (300 µg) per lane were loaded onto 
10% SDS-polyacrylamide gel electrophoresis. The 
proteins were blotted onto polyvinylidene difluoride 
(PVDF) membranes (Roche-Germany) at 120 V for 2 
h in transfer buffer (25 mM Tris, 192 mM glycine, and 
20% methanol). PVDF membranes were blocked 
overnight at 4 °C with 5% skim milk in Tris-buffered 
saline containing 0.1% Tween 20 (TBST). After being 
washed 3 times with TBST buffer, the blots were 
incubated with antibodies against MMP9 (1:3000 
dilution; Abcam, Cambridge, UK) and antie dies 
against MMP9 (1:300Abcam, Cambridge, UK) as an 
internal control in blocking buffer (skim milk and 
TBST) and were shaken for 2 h. We washed 
membranes again and incubated them with goat 
polyclonal secondary antibody to rabbit IgG (1:5000 
dilution; Abcam, Cambridge, UK) for 90 min. Finally, 
bands were visualized using BM blue-POD substrate 
(Roche-Germany). 
All experiments were done in triplicate. Statistical 
analysis was done using by nonparametric Kruskal–
Wallis test and pairwise comparisons among groups 
were performed by Mann–Whitney test. All statistical 
analyses were performed with Graph Pad Prism for 
Windows (version 5, Graph Pad, Software Inc., San 
Diego, CA, 2005). Graphs were represented as a 
mean ± standard error of mean, and P < 0.05 was 
considered as the level of significance. 
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Results 
To determine the role of adiponectin protein in 
MMP9 expression in HA/VSMCs in the presence of 
oxLDL, the cells were stimulated with oxLDL alone 
and in the presence of adiponectin for 24 and 48 h. 
Our results show that oxLDL increased MMP9 
expression 2.16 ± 0.24- and 3.32 ± 0.25-fold after 
24 and 48 h, respectively (P < 0.05). An oxLDL-
induced MMP9 expression was markedly inhibited 
by adiponectin. Adiponectin decreased oxLDL-
induced MMP9 expression 34 and 61% after 24 and 
48 h, respectively (P < 0.05) (Figure 1a). 
Melting curves confirmed that the desired 
fragments were specifically amplified. In a parallel 
experiment, western blot analysis confirmed the 
changes observed at mRNA level (Figure 1b). 
 
 
 
Figure 1. The effect of adiponectin on oxLDL-induced 
MMP9 expression after 24 and 48 h; (A) Real time 
PCR analysis of MMP9 mRNA expression levels in 
HA/VSMCs in the presence of oxLDL with or  without 
adiponectin after 24 and 48 h. Values are expressed as 
mean ± SE from two independent experiments 
performed in triplicate. Differences between groups 
were determined as significant at P < 0.05; (B) MMP9 
protein expression levels by western blotting for 24 and 
48 h. β-actin was used as internal control 
*
 Means P< 0.05 compared to the control VSMCs; # Means 
P < 0.05 compared to the oxLDL-exposed VSMCs; 
oxLDL: Oxidized low-density lipoprotein; VSMCs: human 
aortic vascular smooth muscle cells; MMP9: matrix 
metalloproteinase 9; PCR: Polymerase chain reaction 
Discussion 
Our findings indicate that adiponectin reduces 
gene expression and protein mass of MMP9 in a 
time-dependent manner. According to the anti-
inflammatory properties of adiponectin and 
inflammatory role of MMP9, reduction of MMP9 
mRNA observed by the adiponectin in this study 
was not unexpected. Adiponectin exerts protective 
effects on vascular diseases through its direct 
actions on vascular component cells including 
endothelial cells, macrophages, and smooth muscle 
cells.8,20,21 In vitro studies on VSMCs have shown 
that adiponectin can inhibit proliferation and 
migration of VSMCs induced by several 
atherogenic growth factors through inhibition of 
extracellular signal-regulated kinase activation.22 
The results of the present study are consistent with 
previous results, and indicate that adiponectin 
through reducing MMP9 can be effective in 
reducing the risk of cardiovascular disease.22 
Animal studies results have indicated a key role for 
adiponectin in the progression of atherosclerosis.22 
Considering the fact that, the progression and 
stability of atherosclerotic lesions are associated 
with concentrations of metalloproteinases and 
their inhibitors,23 the effect of adiponectin on 
atheroma lesions in these experiments may be due 
to changes occurring in the extracellular matrix. 
The present study has shown that changes in the 
extracellular matrix occurred as the changes in 
MMP9 concentration happened. Our study has 
shown that reduction in MMP9 protein 
concentration is due to decrease in gene expression 
following adiponectin treatment. Experiment on 
macrophage shows that adiponectin augmented 
tissue inhibitor of metalloproteinases-1 (TIMP-1) 
expression without affecting the mRNA, protein 
levels, and activities of MMP-9.24 These results 
together with the fact that adiponectin with 
MMP9/TIMP-1 ratio has an inverse relationship in 
patients with acute coronary syndrome, suggest 
that adiponectin through the balancing of this ratio 
modulates plaque stability.25 The general 
conclusion from these studies that indicate 
adiponectin has protective properties is consistent 
with our findings. Studies performed on 
macrophages have shown that adiponectin has no 
effect on MMP9 expression,24 whereas our study 
shows that adiponectin has a direct effect on the 
mRNA and protein levels of MMP9. It could be 
concluded that the beneficial effect of adiponectin 
is more intense under pathogenic conditions that 
we have established in the presence of oxLDL. 
This demonstrates the value of clinical use of 
adiponectin. In general, adiponectin through 
reducing gene expression of MMP9 might 
contribute to change in the extracellular matrix, 
hence leading to its vasculoprotective activity 
through stabilization of atheroma lesions and 
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reducing rupture of atheroma. It is hoped that 
these findings will lead to better understanding of 
the pathology of atherosclerosis and its treatment. 
Conclusion 
In summary, our findings in this experimental study 
indicate that adiponectin decreased oxLDL-induced 
MMP9 expression. These results suggest that 
adiponectin protects smooth muscle in the vessel 
wall from the damaging effect of oxLDL in 
pathologic condition. 
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